0000905718-19-000246.txt : 20190222 0000905718-19-000246.hdr.sgml : 20190222 20190222164439 ACCESSION NUMBER: 0000905718-19-000246 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190220 FILED AS OF DATE: 20190222 DATE AS OF CHANGE: 20190222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Park West Asset Management LLC CENTRAL INDEX KEY: 0001386928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36351 FILM NUMBER: 19626288 BUSINESS ADDRESS: STREET 1: 900 LARKSPUR LANDING CIRCLE, SUITE 165 CITY: LARKSPUR STATE: CA ZIP: 94939 BUSINESS PHONE: (415) 524-2902 MAIL ADDRESS: STREET 1: 900 LARKSPUR LANDING CIRCLE, SUITE 165 CITY: LARKSPUR STATE: CA ZIP: 94939 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLx Pharma Inc. CENTRAL INDEX KEY: 0001497504 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271707962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: (713) 842-1249 MAIL ADDRESS: STREET 1: 8285 EL RIO STREET STREET 2: SUITE 130 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20140313 FORMER COMPANY: FORMER CONFORMED NAME: Dipexium Pharmaceuticals, LLC DATE OF NAME CHANGE: 20100726 4 1 plxpharm_fm4feb202019.xml X0306 4 2019-02-20 0 0001497504 PLx Pharma Inc. PLXP 0001386928 Park West Asset Management LLC 900 LARKSPUR LANDING CIRCLE, SUITE 165 LARKSPUR CA 94939 0 0 1 0 Series A Convertible Preferred Stock 2.60 2019-02-20 4 P 0 15000 1000 A 2019-02-20 Common Stock 5769230 15000 I See Footnotes Park West Asset Management LLC (the "Reporting Person") is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company ("PWIMF"), and Park West Partners International, Limited, a Cayman Islands exempted company ("PWPI" and, together with PWIMF, the "PW Funds"). Peter S. Park ("Mr. Park") is the sole member and manager of the Reporting Person. Each share of Series A Convertible Preferred Stock, par value $0.001 per share ("Series A Preferred Stock"), of PLx Pharma Inc. (the "Company") is convertible at any time into a number of shares of common stock, par value $0.001 ("Common Stock"), of the Company equal to the stated value (initially $1,000) divided by the conversion price (initially $2.60), in each case subject to customary adjustments under the certificate of designations for the Series A Preferred Stock (the "Certificate of Designations"). Unless converted pursuant to its terms, the Series A Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.9% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion. As of February 20, 2019, PWIMF held 13,565 shares of Series A Preferred Stock and PWPI held 1,435 shares of Series A Preferred Stock. Pursuant to Reg. Section 240.16a-1(a)(2), the Reporting Person's and Mr. Park's beneficial ownership is limited to their pecuniary interest, if any, in such securities. /s/ Grace Jimenez, Chief Financial Officer of Park West Asset Management LLC 2019-02-22